End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
994 KRW | +8.52% | -.--% | -80.70% |
Mar. 29 | CANARIABIO Inc.(KOSDAQ:A016790) dropped from S&P Global BMI Index | CI |
Jan. 24 | Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis | MT |
Sales 2022 | 158B 115M | Sales 2023 | 161B 117M | Capitalization | 927B 674M |
---|---|---|---|---|---|
Net income 2022 | -283B -206M | Net income 2023 | -208B -151M | EV / Sales 2022 | 4.42 x |
Net Debt 2022 | 118B 85.45M | Net Debt 2023 | 106B 77.1M | EV / Sales 2023 | 6.43 x |
P/E ratio 2022 |
-1.62
x | P/E ratio 2023 |
-3.87
x | Employees | 78 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.53% |
1 day | +8.52% | ||
3 months | -32.52% | ||
6 months | -81.17% | ||
Current year | -80.70% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - |
1st Jan change | Capi. | |
---|---|---|
-80.70% | 136M | |
+11.33% | 11.43B | |
-0.75% | 5.77B | |
-4.08% | 4.87B | |
-23.66% | 2.58B | |
-5.06% | 1.75B | |
-24.53% | 1.11B | |
-23.66% | 882M | |
-18.46% | 865M | |
+24.67% | 855M |
- Stock Market
- Equities
- A016790 Stock